Last reviewed · How we verify
Paclitaxel and Sorafenib
Paclitaxel and Sorafenib is a Small molecule drug developed by Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH. It is currently in Phase 2 development. Also known as: sorafenib = nexavar.
At a glance
| Generic name | Paclitaxel and Sorafenib |
|---|---|
| Also known as | sorafenib = nexavar |
| Sponsor | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer (PHASE2)
- Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer (PHASE1)
- Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer (PHASE2)
- SNF Platform Study of HR+/ HER2-advanced Breast Cancer (PHASE2)
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (PHASE1)
- High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia (NA)
- Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE2)
- QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paclitaxel and Sorafenib CI brief — competitive landscape report
- Paclitaxel and Sorafenib updates RSS · CI watch RSS
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH portfolio CI
Frequently asked questions about Paclitaxel and Sorafenib
What is Paclitaxel and Sorafenib?
Paclitaxel and Sorafenib is a Small molecule drug developed by Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH.
Who makes Paclitaxel and Sorafenib?
Paclitaxel and Sorafenib is developed by Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH (see full Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH pipeline at /company/gesellschaft-fur-medizinische-innovation-hamatologie-und-onkologie-mbh).
Is Paclitaxel and Sorafenib also known as anything else?
Paclitaxel and Sorafenib is also known as sorafenib = nexavar.
What development phase is Paclitaxel and Sorafenib in?
Paclitaxel and Sorafenib is in Phase 2.
Related
- Manufacturer: Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH — full pipeline
- Also known as: sorafenib = nexavar
- Compare: Paclitaxel and Sorafenib vs similar drugs
- Pricing: Paclitaxel and Sorafenib cost, discount & access